BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment.
Gojkovic. Slaven S; Krezic. Ivan I; Vranes. Hrvoje H; Zizek. Helena H; Drmic. Domagoj D; Horvat Pavlov. Katarina K; Petrovic. Andrea A; Batelja Vuletic. Lovorka L; Milavic. Marija M; Sikiric. Suncana S; Stilinovic. Irma I; Samara. Mariam M; Knezevic. Mario M; Barisic. Ivan I; Sjekavica. Ivica I; Lovric. Eva E; Skrtic. Anita A; Seiwerth. Sven S; Sikiric. Predrag P
Key Findings
- BPC‑157 administered shortly after or even 24‑48 h after a permanent superior sagittal sinus blockage dramatically lowered intracranial pressure and brain swelling in rats.
- The peptide rapidly recruited collateral venous pathways (e.g., para‑sagittal veins, azygos‑inferior caval connections) restoring blood flow to the brain and peripheral organs.
- Multiple organ dysfunctions (heart, lung, liver, kidney, gastrointestinal lesions) caused by the venous occlusion were markedly improved with BPC‑157 treatment.
Practical Outcomes
- For biohackers, this suggests BPC‑157 may have fast‑acting vascular‑protective and angiogenic effects that could be useful in acute injuries or conditions involving blocked veins or high intracranial pressure. A dose around 10 µg/kg given orally, intraperitoneally, or locally, within minutes to a couple of days after the event, showed benefit in the animal model. While human data are lacking, the study supports exploring BPC‑157 for rapid collateral circulation support and organ protection after severe vascular insults.
Summary
In a rat study where a major brain vein was permanently blocked, giving the peptide BPC‑157 (about 10 µg per kilogram) quickly reduced brain swelling, lowered dangerous pressure spikes, and opened up new blood‑flow routes both in the brain and the rest of the body. The peptide helped protect the heart, lungs, liver, kidneys and gut from damage caused by the blockage, even when given up to two days after the injury.
Abstract
We show the complex syndrome of the occluded superior sagittal sinus, brain swelling and lesions and multiple peripheral organs lesions in rat. Recovery goes centrally and peripherally, with the stable gastric pentadecapeptide BPC 157, which alleviated peripheral vascular occlusion disturbances, rapidly activating alternative bypassing pathways. Assessments were gross recording, venography, ECG, pressure, microscopy, biochemistry. The increased pressure in the superior sagittal sinus, portal and caval hypertension, aortal hypotension, arterial and venous thrombosis, severe brain swelling and lesions (cortex (cerebral, cerebellar), hypothalamus/thalamus, hippocampus), particular veins (azygos, superior mesenteric, inferior caval) dysfunction, heart dysfunction, lung congestion as acute respiratory distress syndrome, kidney disturbances, liver failure, and hemorrhagic lesions in gastrointestinal tract were all assessed. Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally, intragastrically, or topically to the swollen brain at 1 min ligation-time, or at 15 min, 24 h and 48 h ligation-time. BPC 157 therapy rapidly attenuates the brain swelling, rapidly eliminates the increased pressure in the ligated superior sagittal sinus and the severe portal and caval hypertension and aortal hypotension, and rapidly recruits collateral vessels, centrally ((para)sagittal venous collateral circulation) and peripherally (left superior caval vein azygos vein-inferior caval vein). In conclusion, as shown by all assessments, BPC 157 acts against the permanent occlusion of the superior sagittal sinus and syndrome (i.e., brain, heart, lung, liver, kidney, gastrointestinal lesions, thrombosis), given at 1 min, 15 min, 24 h or 48 h ligation-time. BPC 157 therapy rapidly overwhelms the permanent occlusion of the superior sagittal sinus in rat.
Study Information
pubmed
2021
2021-06-28T00:00:00.000Z
10.3390/biomedicines9070744
29
83